Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors
Open Access
- 5 September 2014
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 25 (11) , 2244-2251
Abstract
Lucitanib is a potent, oral inhibitor fibroblast growth factor receptor types 1 and 2 (FGFR), vascular endothelial growth factor receptor types 1, 2, and 3 (VEGFR), platelet-derived growth factor receptor types α and β (PGFRα/β), which are essential kinases for tumor growth, survival, migration, and angiogenesis. Several tumor types, including breast carcinoma, demonstrate amplification of fibroblast growth factor (FGF)-related genes. There are no approved drugs for molecularly defined FGF-aberrant (FGFR1- or FGF3/4/19-amplified) tumors. This open-label phase I/IIa study involved a dose-escalation phase to determine maximum tolerated dose (MTD), recommended dose (RD), and pharmacokinetics of lucitanib in patients with advanced solid tumors, followed by a dose-expansion phase to obtain preliminary evidence of efficacy in patients who could potentially benefit from treatment (i.e. with tumors harboring FGF-aberrant pathway or considered angiogenesis-sensitive). Doses from 5 to 30 mg were evaluated with dose-limiting toxic effects dominated by vascular endothelial growth factor (VEGF) inhibition-related toxic effects at the 30 mg dose level (one case of grade 4 depressed level of consciousness and two cases of grade 3 thrombotic microangiopathy). The most common adverse events (all grades, all cohorts) were hypertension (91%), asthenia (42%), and proteinuria (57%). Exposure increased with dose and t½ was 31–40 h, suitable for once daily administration. Seventy-six patients were included. All but one had stage IV; 42% had >3 lines of previous chemotherapy. Sixty-four patients were assessable for response; 58 had measurable disease. Clinical activity was observed at all doses tested with durable Response Evaluation Criteria In Solid Tumors (RECIST) partial responses in a variety of tumor types. In the angiogenesis-sensitive group, objective RECIST response rate (complete response + partial response) was 26% (7 of 27) and progression-free survival (PFS) was 25 weeks. In assessable FGF-aberrant breast cancer patients, 50% (6 of 12) achieved RECIST partial response with a median PFS of 40.4 weeks for all treated patients. Lucitanib has promising efficacy and a manageable side-effect profile. The spectrum of activity observed demonstrates clinical benefit in both FGF-aberrant and angiogenesis-sensitive populations. A comprehensive phase II program is planned.Keywords
This publication has 26 references indexed in Scilit:
- Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in CancerClinical Cancer Research, 2012
- CXCR4 Activation Defines a New Subgroup of Sonic Hedgehog–Driven MedulloblastomaCancer Research, 2012
- Development and validation of a high‐performance liquid chromatography–tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E‐3810 in human plasma and its application in a clinical pharmacokinetic studyJournal of Mass Spectrometry, 2011
- Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung CancerPLOS ONE, 2011
- E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical ModelsCancer Research, 2011
- Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancerBreast Cancer Research and Treatment, 2010
- FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast CancerCancer Research, 2010
- Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targetsOncogene, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- FGFR1 amplification in breast carcinomas: a chromogenic in situhybridisation analysisBreast Cancer Research, 2007